Association Between Cannabis Use and Complications Related to Crohn's Disease: A Retrospective Cohort Study.
Abdominal Abscess
/ epidemiology
Adult
Blood Transfusion
/ methods
Colectomy
/ methods
Correlation of Data
Crohn Disease
/ complications
Female
Humans
Intestinal Fistula
/ epidemiology
Male
Marijuana Abuse
/ epidemiology
Middle Aged
Parenteral Nutrition
/ methods
Prevalence
Propensity Score
Retrospective Studies
United States
/ epidemiology
Cannabis
Complications
Crohn’s
Parenteral nutrition
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
27
09
2018
accepted:
20
02
2019
pubmed:
3
3
2019
medline:
8
5
2020
entrez:
3
3
2019
Statut:
ppublish
Résumé
Crohn's disease is an idiopathic inflammatory process that is occasionally associated with complications, which cause significant morbidity and mortality. The anti-inflammatory effect of cannabis in intestinal inflammation has been shown in several experimental models; it is unknown whether this correlates with fewer complications in Crohn's disease patients. To compare the prevalence of Crohn's disease-related complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn's disease or a primary diagnosis of Crohn's related complication and a secondary diagnosis of Crohn's disease between 2012 and 2014. We used data from the Healthcare Cost and Utilization Project-National Inpatient Sample. Cannabis users (615) were compared directly after propensity score match to non-users, in aspects of various complications and clinical end-points. Among matched cohorts, Cannabis users were less likely to have the following: active fistulizing disease and intra-abdominal abscess (11.5% vs. 15.9%; aOR 0.68 [0.49 to 0.94], p = 0.025), blood product transfusion (5.0% vs. 8.0%; aOR 0.48 [0.30 to 0.79], p = 0.037), colectomy (3.7% vs. 7.5%; aOR 0.48 [0.29-0.80], p = 0.004), and parenteral nutrition requirement (3.4% vs. 6.7%, aOR 0.39 [0.23 to 0.68], p = 0.009). Cannabis use may mitigate several of the well-described complications of Crohn's disease among hospital inpatients. These effects could possibly be through the effect of cannabis in the endocannabinoid system.
Sections du résumé
BACKGROUND
Crohn's disease is an idiopathic inflammatory process that is occasionally associated with complications, which cause significant morbidity and mortality. The anti-inflammatory effect of cannabis in intestinal inflammation has been shown in several experimental models; it is unknown whether this correlates with fewer complications in Crohn's disease patients.
AIMS
To compare the prevalence of Crohn's disease-related complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn's disease or a primary diagnosis of Crohn's related complication and a secondary diagnosis of Crohn's disease between 2012 and 2014.
METHODS
We used data from the Healthcare Cost and Utilization Project-National Inpatient Sample. Cannabis users (615) were compared directly after propensity score match to non-users, in aspects of various complications and clinical end-points.
RESULTS
Among matched cohorts, Cannabis users were less likely to have the following: active fistulizing disease and intra-abdominal abscess (11.5% vs. 15.9%; aOR 0.68 [0.49 to 0.94], p = 0.025), blood product transfusion (5.0% vs. 8.0%; aOR 0.48 [0.30 to 0.79], p = 0.037), colectomy (3.7% vs. 7.5%; aOR 0.48 [0.29-0.80], p = 0.004), and parenteral nutrition requirement (3.4% vs. 6.7%, aOR 0.39 [0.23 to 0.68], p = 0.009).
CONCLUSION
Cannabis use may mitigate several of the well-described complications of Crohn's disease among hospital inpatients. These effects could possibly be through the effect of cannabis in the endocannabinoid system.
Identifiants
pubmed: 30825109
doi: 10.1007/s10620-019-05556-z
pii: 10.1007/s10620-019-05556-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2939-2944Commentaires et corrections
Type : CommentIn
Références
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G364-71
pubmed: 16574988
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
Gastroenterology. 2007 Oct;133(4):1327-39
pubmed: 17919503
Nat Genet. 2008 Aug;40(8):955-62
pubmed: 18587394
J Mol Cell Cardiol. 2009 May;46(5):612-20
pubmed: 19162037
Inflamm Bowel Dis. 2009 Nov;15(11):1678-85
pubmed: 19408320
Hepatology. 2011 Jan;53(1):346-55
pubmed: 21254182
Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6
pubmed: 21795981
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Isr Med Assoc J. 2011 Aug;13(8):455-8
pubmed: 21910367
Toxicol Appl Pharmacol. 2012 Jan 15;258(2):256-67
pubmed: 22119709
Hum Genet. 2012 Jun;131(6):779-89
pubmed: 22543841
Int J Biochem Cell Biol. 2012 Nov;44(11):2028-31
pubmed: 22842535
Life Sci. 2013 May 30;92(20-21):976-83
pubmed: 23567807
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1276-1280.e1
pubmed: 23648372
Inflamm Bowel Dis. 2013 Dec;19(13):2809-14
pubmed: 24185313
Inflamm Bowel Dis. 2014 Mar;20(3):472-80
pubmed: 24407485
Biochem Biophys Res Commun. 2014 Sep 5;451(4):516-21
pubmed: 25111814
Drug Alcohol Depend. 2015 Nov 1;156:84-89
pubmed: 26422462
J Stroke Cerebrovasc Dis. 2016 Feb;25(2):452-60
pubmed: 26708529
J Stroke Cerebrovasc Dis. 2017 Jan;26(1):217-224
pubmed: 27810149
N Engl J Med. 2017 Feb 23;376(8):705-707
pubmed: 28225673
PLoS One. 2017 Apr 25;12(4):e0176416
pubmed: 28441459
PLoS One. 2017 Aug 24;12(8):e0182900
pubmed: 28837634